Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma – Authors' reply

EORTC CATNON investigators

Research output: Contribution to journalArticleProfessionalpeer-review

Original languageEnglish
Pages (from-to)e346
JournalThe Lancet Oncology
Issue number8
Publication statusPublished - 1 Aug 2021

Bibliographical note

Funding Information:
MJvdB reports grants from the Dutch Cancer Foundation, Brain Tumor Charity, Strijd van Salland, and Merck Sharp & Dohme (formerly Schering Plough), during the conduct of the study; and personal fees from Carthera, Nerviano, Bayer, Cellgene, Agios, AbbVie, Karyopharm, Boston Pharmaceuticals, and Genenta, outside the submitted work. MT declares no competing interests.

Cite this